Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.40 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28691740 | 0.82 | SMN1; SMN2 (0.53) | SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL6313251 | 0.78 | KDM4E (0.49) | CYP2C19SMN1; SMN2TDP1KDM4EALDH1A1 | |
| SCHEMBL6316170 | 0.70 | NPSR1 (0.42) | L3MBTL1 | |
| SCHEMBL3337034 | 0.70 | CYP1A1 (0.65) | SMN1; SMN2KDM4EALDH1A1CYP1A1POLB | |
| SCHEMBL2896689 | 0.68 | POLB (0.56) | SMN1; SMN2KDM4EALDH1A1HPGDPOLB | |
| SCHEMBL3333827 | 0.68 | L3MBTL1 (0.60) | SMN1; SMN2ALDH1A1CYP1A1POLBBCHE | |
| SCHEMBL2207254 | 0.66 | L3MBTL1 (0.59) | KDM4EALDH1A1HPGDHSD17B10POLB | |
| SCHEMBL9945977 | 0.66 | RAB9A (0.68) | SMN1; SMN2ALDH1A1HPGDCYP1A1POLB | |
| SCHEMBL6653640 | 0.66 | MAPK1 (0.44) | SMN1; SMN2KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL9850229 | 0.65 | CYP2C19 (0.62) | CYP2C19SMN1; SMN2TDP1KDM4ESHMT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050014810-A1 | Use of substituted 2 phenylbenzimidazoles as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014810-A1 | Use of substituted 2 phenylbenzimidazoles as medicaments | GLP1R, GIPR, GCGR | CYP2C19 462/4885SMN1; SMN2 4132/4885TDP1 4057/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.